HSV-2 theracine

DB05811ExperimentalProtein Based Therapies

HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

Primary indication
Investigated for use/treatment in genital herpes.Curator reviewed

What you can answer from here — as of April 02, 2025

1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of HSV-2 theracine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In